DSP lays out aggressive new goals as it aims to get growth back on track
This article was originally published in Scrip
Executive Summary
Dainippon Sumitomo Pharma (DSP) has laid out a comprehensive new mid-term business plan that outlines a variety of measures including speeding up product development, cost savings, licensing deals and even possible acquisitions to address the lagging performance of some key strategic drugs and threats to Japanese sales of older products.